Mozart Therapeutics
Julie Gilmore is the Site Head and Chief Operating Officer for Lilly Gateway Labs, a shared innovation lab located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. She joined Eli Lilly after receiving her Doctorate in Membrane Biophysics from Purdue University and her Postdoctoral Fellowship in Drug Transport from Indiana University School of Medicine. During her 20-year plus career at Lilly, Julie has held several leadership and scientific positions across research and drug development, including Head of Information Sciences and Clinical Operations for Lilly Europe, Global Head of Scientific Communications, and most recently, Senior Director of Portfolio Management for the Neurodegeneration and Pain Early Phase Portfolio. Julie is on the Board of Governors for BioCom and the Board of Directors for California Life Sciences. She also serves as a mentor and advisor to several university graduate school programs including locally at UCSF.
This person is not in the org chart
This person is not in any offices
Mozart Therapeutics
Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.